News
Featured
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed that of all previous years. The WGND is tracking 19 drug candidates that have initiated or completed a Phase 1 clinical trial for use in treating Tuberculosis. Most have been or are currently being evaluated in a Phase 2 clinical trial and one has made it to Phase 3. These 19 do...
News
21 Mar 2011
TB R&D Weekly Update: TB Drug Resistance and Treatment Delays with Fluoroquinolone Use for Pneumonia
Chen TC, Lu PL, Lin CY, Lin WR, Chen YH. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2011 Mar;15(3):e211-6. Epub 2010 Dec 30. Chen, et al., conducted a meta-analysis to ascertain the answer to two...
16 Mar 2011
Photo: David Rochkind On World TB Day March 24, there will be a Congressional Briefing on multi-drug resistant TB (MDR-TB) where David Rochkind, the award winning photographer and Pulitzer Center grantee, will present his reporting and photography on his exploration into the MDR-TB crisis in...
14 Mar 2011
Summary: Dr. Eric Nuermberger is Associate Professor of Medicine in the Division of Infectious Diseases, Department of Medicine, at Johns Hopkins University School of Medicine. The WGND had the opportunity to talk with Dr. Nuermberger on a recent article entitled “PA-824 exhibits time-dependent...
9 Mar 2011
Global Health Primer by Disease This week BIO Ventures for Global Health launched a new online tool called the “Global Health Primer” which aims to be a clearinghouse of information geared to the biotech industry to encourage investments in neglected disease product development. The Primer...
7 Mar 2011
[wpaudio url=”/blog/media/podcasts/Andersen_Peter_finished.mp3″ text=”Click here to play the Peter Anderson Podcast” dl=”0″] Summary: Dr. Peter Andersen is Vice President of Vaccine Research and Development at Statens Serum Institut (SSI). The WGND had the opportunity to talk with Dr. Andersen on a...
3 Mar 2011
From Guardian (UK) (March 3, 2011) AstraZeneca has joined a consortium to fight tuberculosis around the world with French rival Sanofi-aventis, the University of Cambridge and other research organisations. The More Medicines for Tuberculosis (MM4TB) consortium intends to develop new drugs for...
2 Mar 2011
2010 G-Finder Report The third annual G-Finder report, Neglected Disease Research and Development, was released on February 16, 2011. The report, compiled by the Policy Cures staff using information self-reported by granting and recipient institutions, provides the latest information on the funding...
28 Feb 2011
Elkington PT, D’Armiento JM, Friedland JS. Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci Transl Med. 2011 Feb 23;3(71):71ps6. In today’s article, Elkington, et al., would like to change how researchers view and define immunopathology in tuberculosis. The...
23 Feb 2011
In addition, other discussions in the policy realm toss around the idea that the government should get a return on the sale of drugs that were developed with federal funds in the face of high drug costs and medical care. This debate surrounding the public sectors role in downstream drug development...
22 Feb 2011
The Revista Panamericana de Salud Pública / Pan American Journal of Public Health , published by the Pan American Health Organization , announces an open call for original papers, brief communications, and reviews for its next special issue, which will cover topics related to antimicrobial...
21 Feb 2011
Summary: Dr. Philip Bourne is a professor at the University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences and Editor in Chief of PL0S Computational Biology . The WGND had the opportunity to talk with Dr. Bourne on a recent article published in PLoS Computational...
16 Feb 2011
Dr. Rajiv Shah, Administrator of the United States Agency for International Development (USAID), addressed the importance of investing in innovation and harnessing the power of new global health technologies to achieve widespread impact on those suffering from disease in the most impoverished...
14 Feb 2011
[wpaudio url=”/blog/media/podcasts/Anne_Lenaerts_Interview_edited-norm.mp3″ text=”Anne Lenaerts Interview” dl=”0″] Summary: Dr. Anne Lenaerts is an associate professor at Colorado State University”s College of Veterinary Medicine and Biomedical Sciences in the Department of Microbiology, Immunology...
9 Feb 2011
The Bill & Melinda Gates Foundation is now accepting letters of inquiry for the new grant program Biomarkers for the Diagnosis of Tuberculosis. This grant program is part of the Grand Challenges in Global Health initiative. With up to $12 million of funding, the program seeks to validate...
7 Feb 2011
Chemical Structure of Pyrazinamide Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis. Antimicrob Agents Chemother. 2011 Jan 31. [Epub ahead of print] First discovered as...
